About Integrated Development Associates
Integrated Development Associates is a Healthcare company based in Tokyo (Japan) founded in 2004, and was acquired by Chiltern International in May 2017. Full-service CRO, based out of Japan and Asia and also offering regulatory consulting services. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service.
Company details
Integrated Development Associates (IDA), acquired by Chiltern in May, 2017, is a full-service CRO also specialising in providing product development and regulatory consulting services mainly for new biopharmaceutical products in Japan and Asia. Their key service offerings include development of the market entry strategy (medical and scientific analysis, product positioning in Japan), regulatory services (KOL interactions, PMDA interactions), comprehensive clinical development services (turnkey Phase 1 and Phase 2-4 implementation), Clinical Trial In-Country Caretaker (CT-ICC) services for Japanese clinical trial conduct, and filing and maintenance of official submissions to MHLW on behalf of clients. The company claims to be one of the 5 companies to have received SAKIGAKE Designation (breakthrough therapy) from the Japanese authorities. IDA has experience in a wide range of therapeutic areas including CNS, metabolic, cardiovascular and infectious diseases, oncology (almost all types) and orphan diseases. They also have experience in developing cell therapies and regenerative medicine.
- Headquarters Tokyo, Japan
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website i-d-a.com
- Social LinkedIn Facebook
- Acquired by Chiltern International (May 2017)
- Investors
- Acquired byChiltern International
(May 2017)
Investors in Integrated Development Associates
Integrated Development Associates has secured backing from 1 investor. Prominent investors backing the company include Chiltern International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Full service CRO with expertise in oncology related development services | 1982 | chiltern.com | Berkshire County, United States |
Investor details for Integrated Development Associates
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Integrated Development Associates
2 dated milestones of Integrated Development Associates across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Integrated Development Associates is founded.
- Exit Acquired by Chiltern International.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Integrated Development Associates
Integrated Development Associates was founded in 2004.
Integrated Development Associates is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Integrated Development Associates (IDA), acquired by Chiltern in May, 2017, is a full-service CRO also specialising in providing product development and regulatory consulting services mainly for new biopharmaceutical products in Japan and Asia. Their key service offerings include development of the market entry strategy (medical and scientific analysis, product positioning in Japan), regulatory services (KOL interactions, PMDA interactions), comprehensive clinical development services (turnkey Phase 1 and Phase 2-4 implementation), Clinical Trial In-Country Caretaker (CT-ICC) services for Japanese clinical trial conduct, and filing and maintenance of official submissions to MHLW on behalf of clients. The company claims to be one of the 5 companies to have received SAKIGAKE Designation (breakthrough therapy) from the Japanese authorities. IDA has experience in a wide range of therapeutic areas including CNS, metabolic, cardiovascular and infectious diseases, oncology (almost all types) and orphan diseases. They also have experience in developing cell therapies and regenerative medicine.
Integrated Development Associates has 1 investor. Key investors include Chiltern International.
Yes. Integrated Development Associates was acquired by Chiltern International in May 2017.
